Global Scleroderma Market Forecasts Promising Growth with Latest Industry Trends by 2027

Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Global Scleroderma Market Report 2023" report has been added to * ResearchAndMarkets.com's* offering.

The global scleroderma market is poised for expansion, with predictions revealing a notable surge from $2 billion in 2022 to an estimated $2.78 billion by 2027. The comprehensive market study demonstrates a compound annual growth rate (CAGR) of 7.5% for the year 2023 and an expected CAGR of 6.6% over the subsequent four years. Amidst challenging economic landscapes shaped by geopolitical instability and health crises, the scleroderma industry remains resilient, pushing forward with innovative treatments and increasing prevalence as key growth drivers.

The rising incidence of scleroderma globally has spotlighted the urgent need for advanced therapeutics and diagnostics. The condition, characterized by excessive collagen production and autoimmune irregularities, affects millions worldwide. In light of this growing prevalence, industry leaders are channeling resources into developing novel treatments poised to redefine standards of care and improve patient outcomes.

Bolstered by groundbreaking research findings and regulatory milestones, the market is witnessing a surge of cutting-edge therapies. Innovations such as first-in-class immunomodulators are setting new precedents, offering hope to patients grappling with complex manifestations of scleroderma, including interstitial lung disease.

In the geographical market landscape, North America continues to dominate the scleroderma space, while Asia-Pacific emerges as the fastest-growing region, signaling a dynamic shift in the global healthcare map. Robust advancements and strategic market presence underpin the market dominance of established entities and up-and-coming players alike.

With strategic acquisitions shaping the market's contours, companies such as Sanofi S.A. are broadening their portfolios and fortifying their commitment to addressing unmet medical needs. The integration of innovative candidates like Belumosudil cements Sanofi's dedication to combating diffuse cutaneous systemic sclerosis (dcSSc) and other scleroderma-related conditions.

The recently published scleroderma market report offers an intricate analysis, encompassing a variety of treatments ranging from medication to surgical interventions. The exhaustive research provides clarity on revenues generated by entities involved in offering medicinal solutions, thereby piecing together a holistic view of the scleroderma market's trajectory.

*Key Highlights of the Global Scleroderma Market Report:*

· Projected market growth to $2.78 billion by 2027 with a CAGR of 6.6% from 2023 to 2027
· Focus on the escalating prevalence driving demand for advanced scleroderma treatments
· Introduction of novel therapeutics such as immunomodulators transforming patient care
· Analysis of strategic acquisitions to enhance pharmaceutical portfolios and research capabilities
· Comprehensive segment and regional market coverage, including extensive company profiling
· Insightful exploration of treatment and revenue benchmarks shaping market dynamics

This report furnishes stakeholders, healthcare providers, investors, and pharmaceutical companies with a detailed compass to navigate the complexities of the scleroderma market, heralding a paradigm of informed decision-making and strategic planning.

*Key Attributes:*

*Report Attribute* *Details*
No. of Pages 175
Forecast Period 2023 - 2027
Estimated Market Value (USD) in 2023 $2.15 billion
Forecasted Market Value (USD) by 2027 $2.78 billion
Compound Annual Growth Rate 6.6%
Regions Covered Global

*A selection of companies mentioned in this report includes*

· Pfizer Inc.
· Johnson And Johnson Inc.
· F. Hoffmann-La Roche AG
· Abbvie Inc.
· Bayer AG
· Novartis AG
· Merck And Co. Inc.
· Sanofi S.A.
· Bristol-Myers Squibb Company
· AstraZeneca plc
· Takeda Pharmaceutical Company Limited
· Eli Lilly and Company
· Gilead Sciences Inc.
· Amgen Inc.
· GSK plc
· Teva Pharmaceutical Industries Ltd.
· Astellas Pharma Inc.
· Aspen Pharmacare Holdings Limited
· Boehringer Ingelheim International GmbH
· Principia Biopharma Corp
· aTyr Pharma Inc.
· Cumberland Pharmaceuticals Inc.
· Kadmon Holdings Inc.
· Emerald Health Pharmaceuticals Inc.
· FibroGen Inc.
· Argentis Pharmaceuticals LLC
· Corbus Pharmaceuticals Holdings Inc.
· Celgene Corporation
· Actelion Pharmaceuticals Inc.
· H.A.C. Pharma

For more information about this report visit https://www.researchandmarkets.com/r/tx5tez

*About ResearchAndMarkets.com*
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

*Attachment*

· Global Scleroderma Market

CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900